NASDAQ:XERS Xeris Biopharma Q2 2026 Earnings Results & Report $10.48 +0.29 (+2.85%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$10.46 -0.02 (-0.19%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Xeris Biopharma missed analyst earnings expectations but beat on revenue in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.18 versus the $0.0121 consensus estimate, while revenue of $92.10 million topped the $90.13 million estimate by $1.97 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 6, 2026TimeBefore Market OpensConference Call8:30 AM ET Xeris Biopharma EPS ResultsActual EPS-$0.18Consensus EPS $0.0121Beat/MissMissed by -$0.1921One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersXeris Biopharma Revenue ResultsActual Revenue$92.10 millionExpected Revenue$90.13 millionBeat/MissBeat by +$1.97 millionYoY Revenue GrowthN/AUpcoming EarningsXeris Biopharma's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileConference Call Audio Live Call not available Earnings Conference CallXeris Biopharma Q2 202600:00 / 00:00Speed:1x1.25x1.5x2xPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Xeris Biopharma Q2 2026 Earnings FAQ Did Xeris Biopharma beat earnings estimates for Q2 2026? Xeris Biopharma (NASDAQ:XERS) reported earnings of -$0.18 per share for Q2 2026, missing the consensus estimate of $0.0121. The report was announced on Thursday, August 6, 2026. What was Xeris Biopharma's revenue for Q2 2026? Xeris Biopharma reported revenue of $92.10 million for Q2 2026, against a consensus estimate of $90.13 million. Where can I read Xeris Biopharma's Q2 2026 earnings call transcript? The full Xeris Biopharma Q2 2026 earnings conference call transcript is published on this page, including prepared remarks and the analyst Q&A session, along with the participants who spoke on the call. When is Xeris Biopharma's next earnings date? Xeris Biopharma's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Xeris Biopharma on the company's earnings history page. Xeris Biopharma Earnings HeadlinesWhy Xeris Biopharma Holdings (XERS) Is Up 5.8% After Raising 2026 Revenue Guidance And Retiring DebtOctober 8 at 10:42 PM | finance.yahoo.comXeris Biopharma (NASDAQ:XERS) Stock Price Up 9.2% - Should You Buy?October 5, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)Xeris Biopharma (NASDAQ:XERS) Insider Steven Pieper Sells 5,000 Shares of Company StockOctober 3, 2026 | americanbankingnews.comXeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,666 Shares of StockOctober 3, 2026 | americanbankingnews.comXeris Biopharma (NASDAQ:XERS) Stock: Insider Kevin Mcculloch Sells 25,000 SharesOctober 1, 2026 | americanbankingnews.comSee More Xeris Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xeris Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xeris Biopharma and other key companies, straight to your email. Email Address About Xeris BiopharmaXeris Biopharma (NASDAQ:XERS), Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms. Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing’s syndrome. The company also markets Ogluo, a glucagon autoinjector, in certain markets. Its products are primarily marketed in the United States, with selected international availability supported through commercial partners and regional arrangements. The company was established as Xeris Pharmaceuticals and became a publicly traded company in 2018. In 2021, Xeris completed a combination with Strongbridge Biopharma, expanding its portfolio and adding therapies focused on rare endocrine diseases. In addition to its commercial products, Xeris continues to develop medicines and drug-delivery applications based on its proprietary formulation platforms.View Xeris Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
